Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Sangamo Therapeutics (NASDAQ:SGMO) Share Price

Press coverage about Sangamo Therapeutics (NASDAQ:SGMO) has been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.8436295797827 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern’s scoring:

Shares of Sangamo Therapeutics (SGMO) opened at $16.45 on Wednesday. Sangamo Therapeutics has a twelve month low of $2.65 and a twelve month high of $18.40. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $10.37 million. During the same period in the previous year, the firm posted ($0.27) earnings per share. The business’s revenue was up 333.0% compared to the same quarter last year. analysts predict that Sangamo Therapeutics will post -0.73 EPS for the current year.

SGMO has been the subject of several research reports. Jefferies Group reissued a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Friday, August 18th. Wedbush reissued a “hold” rating and issued a $6.00 target price on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Piper Jaffray Companies set a $8.00 price target on Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Thursday, August 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $17.83.

In related news, Director William R. Ringo sold 31,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total value of $445,470.00. Following the completion of the sale, the director now owns 31,800 shares in the company, valued at $456,966. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $15.25, for a total value of $228,750.00. The disclosure for this sale can be found here. Insiders have sold 67,630 shares of company stock valued at $1,015,812 in the last 90 days. Company insiders own 5.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply